Elamipretide
http://dbpedia.org/resource/Elamipretide an entity of type: Thing
Elamipretide (also known as SS-31, , MTP-131 and Bendavia) is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin. Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.
rdf:langString
rdf:langString
Elamipretide
xsd:integer
46652859
xsd:integer
1096103502
xsd:integer
32
xsd:integer
736992
xsd:integer
49
xsd:integer
-6
rdf:langString
D10925
xsd:integer
9
xsd:integer
5
xsd:integer
11764719
xsd:integer
1
rdf:langString
SFVLTCAESLKEHH-WKAQUBQDSA-N
rdf:langString
H-D-Arg-Tyr-Lys-Phe-NH2; (D)-Arginyl-2,6-dimethyl-(L)-tyrosyl-(L)-lysyl-(L)-phenylalaninamide
xsd:integer
87
rdf:langString
Elamipretide (also known as SS-31, , MTP-131 and Bendavia) is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin. Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics. As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication. As of January 2020, trial expectations were not met.
xsd:nonNegativeInteger
4891
xsd:string
736992-21-5
xsd:string
87GWG91S09
xsd:string
D10925
xsd:string
11764719